Overview

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

Status:
Recruiting

Trial end date:
2025-05-19

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the overall survival time (OS), objective remission rate（ORR）, progression-free survival time（PFS）, disease control rate（DCR）of Carelizumab combined with irinotecan and apatinib for the second-line treatment of locally advanced unresectable, recurrent or metastatic adenocarcinoma of stomach and gastroesophageal junction. At the same time, the safety and tolerance of the scheme were preliminarily evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Treatments:

Apatinib
Irinotecan